炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：同花顺投资助手 责任编辑：何俊熹 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：同花顺投资助手 责任编辑：何俊熹 ...

| | 长春高新 97.26 + 10.00% 分时 均线 所属行业: 生物医药 | | | | --- | --- | --- | --- | | 97.26 | | | | | 95.49 | | | | | 93.72 | | | | | 91.96 | | | | | 90.19 | | | | | 88.42 | | | | | 86.65 | | | | | 84.88 | | | | | 83.12 | | | | | 81.35 | | | | | 79.58 | | | | | 1.62万 | | | | | 1.22万 | | | | | 8116 | | | | | 4058 | | | | | LILLE LE LE LE LETT | | | | | 09:30 | 10:30 | 11:30 | 14:00 | 格隆汇2月25日｜长春高新(000661.SZ)尾盘拉升封涨停板，报价97.26元。消息面上，长春高新昨晚公告，子公司金赛药业收到国家药监局批准，GenSci141 软膏(双氢睾酮软膏)境内临床试验申请获准，拟用于儿童小阴茎治疗。该药属化药2.2类/2.4类，为国内首个针对 ...

近日，长春高新发布公告称，子公司金赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准，该药品用于 改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的 原因导致的儿童小阴茎。 （长春高新公告） ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 【导读】A股大涨，韩国股市突破6000点关口 中国基金报记者 泰勒 大家好，今天的A股继续上涨，一起看看发生了什么事情。 A股全线上涨 2月25日，A股主要股指全线上涨。截至收盘，沪指涨0.72%，深成指涨1.29%，创业板指涨1.41%，科创 综指涨超1%。 | 内地股票 △ ◎ | | | | --- | --- | --- | | 行情 | 资金净流入 | 涨跌分布 | | 上证指数 | 深证成指 | 科创综指 | | 4147.23 | 14475.87 | 1819.72 | | +29.82 +0.72% +184.30 +1.29% +21.52 +1.20% | | | | 万得全A | 创业板指 | 北证50 | | 6899.99 | 3354.82 | 1547.20 | | +71.41 +1.05% +46.55 +1.41% +11.77 +0.77% | | | | 沪深300 | 中证500 | 中证A500 | | 4735.89 | 8527.56 | 5967.30 | | +28.34 +0.60 ...

Group 1: Market Performance - The A-share biopharmaceutical ETF Huatai Fuhua (159839) rose by 1.1%, with a total trading volume exceeding 22 million yuan, marking the fourth consecutive day of inflows totaling over 20 million yuan [2] - The Hong Kong biopharmaceutical ETF Huatai Fuhua (513280) fluctuated and closed flat, with a trading volume exceeding 42 million yuan, and a net inflow of over 17 million yuan in the last 60 days [3] - The majority of the popular component stocks in the biopharmaceutical ETF Huatai Fuhua (159839) showed positive performance, with Changchun High-tech hitting the daily limit and its subsidiary GenSci141 ointment receiving clinical trial approval [5] Group 2: Company Performance - WuXi AppTec (药明康德) reported a significant performance increase, with a projected net profit growth of 41.3% in 2025, driven by the TIDES business, which saw revenue growth exceeding 90% [8] - WuXi Biologics (药明生物) achieved a record total of 945 projects, with a 30% growth in dual monoclonal antibodies and ADC projects, indicating strong future revenue potential [8] - The domestic clinical CRO market is expected to return to a growth trajectory in 2025, benefiting companies like Tigermed (泰格医药) from improved order prices and increased clinical pipeline numbers [8] Group 3: Industry Trends - The global CXO industry is expected to continue its strong recovery, with significant investment and transaction demand in the biotech and pharmaceutical sectors anticipated to rebound in 2025 [7] - The Chinese innovative drug market is showing robust activity, with a 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic market [7] - The Chinese innovative drug sector is transitioning from pipeline expectations to revenue realization, with over 70% of companies projected to achieve positive revenue growth in 2025 [11]

Core Viewpoint - The Xinhua 500 Index (989001) closed on February 25 with an increase of 40.00 points, representing a rise of 0.75%, ending at 5360.49 points [1]. Group 1: Index Performance - The Xinhua 500 Index opened slightly higher on the morning of February 25, continued to rise during the early trading session, and saw a gradual narrowing of gains in the afternoon, with a slight rebound towards the end of the trading day [3]. - The index reached a maximum of 5389.16 points and a minimum of 5327.87 points during the trading session [4]. - The total trading volume of constituent stocks for the day was reported at 869 billion yuan, showing a significant increase compared to the previous trading day [4]. Group 2: Constituent Stocks - Notable stocks that hit the daily limit of approximately 10% include Baogang Steel, Shanshan Technology, Yuntianhua, Changchun High-tech, Northern Rare Earth, China Merchants Energy, and Hebang Biotechnology [4]. - Other stocks that rose over 8% include Oriental Yuhong, Chihong Zn & Ge, China Rare Earth, Shenghe Resources, and COSCO Shipping Energy [4]. - Stocks with significant declines include Hengtong Optic-Electric, Lanke Technology, Zhaoyi Innovation, China Duty Free Group, and Yanzhou Coal Mining [4].

EVET 行业称在25年涨价50%的基础上,电子布月度价格继续上调10-15% 卓郎智能 5天3板 公司经营范围包括机器人、机器人系统、机器人应用技术等;此前与国际复材签订了加 捻事业部史上最大额玻璃纤维捻线机订单 再升科技 5天3板 国内微玻璃纤维滤纸行业龙头,为SpaceX出口超高温绝热材料 有潮化工 赤天化 贵州最大的甲醇生产企业;全资子公司桐梓化工拥有甲醇产能30万吨/年,产品主要是 外销,采用世界最先进的德士古技术,甲醇质量可以与天然气装置质量并驾齐驱 沧州大化 1、公司此前共聚硅PC产品投料试车成功,使公司成为国内第一家连续生产法生产共聚 硅PC的企业,填补了该领域国内空白;2、公司拥有烧碱产能16万吨/年 " Hart El W 汉缆股份 4天4板 海上风电产业所需海缆产品的主要供应商之 云计算数据中心 罗曼股份 3天3板 公司拟收购武桐高新39.23%的股权，标的主要从事AIDC算力服务器与集群综合解决方 案服务业务 豫能控股 5天5板 公司筹划参股先天算力,并以先天算力为主体收购郑州合盈控股权,郑州合盈数据主要 从事第三方超大规模数据中心业务，下属数据中心主要分布于河北省张家口市怀来县、 廊 ...

责任编辑：小浪快报 声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 2026年2月25日，长春高新（sz000661）触及涨停，涨停价97.26元，涨幅9.98%，总市值396.68亿元，流 通市值388.59亿元，截止发稿，总成交额14.17亿元。 根据喜娜AI异动分析，长春高新涨停原因可能如下，创新药研发+技术授权+国际化布局： 1、长春高新 呈现"研发驱动+国际化布局"的发展态势。子公司金赛药业在儿科、肿瘤等多个治疗领域创新药研发进 展显著，15个1类新药项目处于不同研发阶段，显示出强大研发实力。公司还通过GenSci098项目技术授 权获得1.2亿美元首付款及潜在13.65亿美元里程碑付款，为长期发展奠定基础。 2、行业来看，医药行 业对创 ...

2月25日，长春高新盘中上涨2.04%，截至14:22，报90.22元/股，成交3.69亿元，换手率1.03%，总市值 368.04亿元。 资料显示，长春高新技术产业(集团)股份有限公司位于吉林省长春市高新海容广场B座27层(震宇街与东 蔚山路交汇),香港铜锣湾希慎道33号利园1期19楼1915室，成立日期1993年6月10日，上市日期1996年12 月18日，公司主营业务涉及生物制药及中成药的研发、生产和销售,辅以房地产开发、物业管理和服务 等业务。主营业务收入构成为：制药业92.83%，房地产6.81%，服务业0.36%。 长春高新所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：疫苗、肝炎治疗、 生物疫苗、东北振兴、阿尔茨海默等。 截至9月30日，长春高新股东户数10.41万，较上期减少4.63%；人均流通股3840股，较上期增加4.85%。 2025年1月-9月，长春高新实现营业收入98.07亿元，同比减少5.60%；归母净利润11.65亿元，同比减少 58.23%。 资金流向方面，主力资金净流入4389.73万元，特大单买入4206.91万元，占比11.42%，卖出1314.96万 ...

Group 1: Financial Performance - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% [1] - Zhongke Shuguang achieved a revenue of 14.97 billion yuan in 2025, growing by 13.86%, with a net profit of 2.113 billion yuan, reflecting a 10.54% increase [2] - Oat Technology's revenue reached 619 million yuan, marking a 24.33% growth, and a net profit of 137 million yuan, up 42.63% [4] - Yongxi Electronics reported a revenue of 4.4 billion yuan, a 21.92% increase, with a net profit of 82.24 million yuan, up 23.99% [5] Group 2: Shareholder Actions - Yashida Optoelectronics announced that a shareholder plans to reduce holdings by up to 1.6 million shares, representing no more than 0.976% of the total share capital [3] - Yuanli Co. intends to repurchase shares worth 50 to 60 million yuan for employee stock ownership plans, with a maximum repurchase price of 20 yuan per share [6] - Conch Cement's controlling shareholder plans to increase holdings by 700 million to 1.4 billion yuan [7] - Huaneng Hydropower's controlling shareholder plans to increase holdings by 100 to 150 million yuan [8] Group 3: Corporate Announcements - Baotai's drug application for Darpobatin injection has been accepted by the National Medical Products Administration [14] - Changchun High-tech's subsidiary received approval for clinical trials of GenSci141 ointment [15] - Tongwei Co. is planning to acquire 100% of Lihua Qingneng, with stock trading suspended for up to 10 trading days [16] - Guoyao Modern's application for the raw material drug Minaprine has been approved [20] Group 4: Market Activities - Kaipu Cloud announced the termination of the acquisition of Nanning Taike [21] - Boji Pharmaceutical plans to reduce its holdings by up to 0.69% of the total share capital [23] - ST Renfu intends to issue shares to its controlling shareholder to raise 3 to 3.5 billion yuan for innovative drug development projects [24] - Huayi Technology submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [25]